- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT04834414
Studio sulle piastrine refrigerate "CHIPS" (CHIPS)
Studio sulle piastrine raffreddate
A phase 3 randomized partial blind storage duration ranging study in patients undergoing complex cardiac surgery that will compare the transfusion of cold stored platelets to standard room temperature stored platelets. The primary objective is to establish that cold stored platelets have a non-inferiority (or superiority) to room temperature platelets.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
Western Australia
-
Murdoch, Western Australia, Australia, 6150
- Fiona Stanley Hospital
-
Nedlands, Western Australia, Australia, 6009
- Sir Charles Gairdner Hospital
-
-
-
-
Arizona
-
Pheonix, Arizona, Stati Uniti, 85054
- Mayo Clinic Arizona
-
Tuscon, Arizona, Stati Uniti, 85713
- Banner University Medical Center
-
-
California
-
Los Angeles, California, Stati Uniti, 90095
- Ronald Reagan UCLA Medical Center
-
-
Florida
-
Gainesville, Florida, Stati Uniti, 32608
- University of Florida
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60611
- Northwestern Memorial Hospital
-
Maywood, Illinois, Stati Uniti, 60153
- Loyola Universtiy Medical Center
-
-
Kansas
-
Kansas City, Kansas, Stati Uniti, 66103
- University of Kansas Medical Center
-
-
Kentucky
-
Lexington, Kentucky, Stati Uniti, 40536
- University of Kentucky
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21287
- John Hopkins
-
-
Michigan
-
Ann Arbor, Michigan, Stati Uniti, 48109
- University of Michigan
-
-
Minnesota
-
Minneapolis, Minnesota, Stati Uniti, 55455
- University of Minnesota
-
Rochester, Minnesota, Stati Uniti, 55905
- Mayo Clinic
-
-
North Carolina
-
Winston-Salem, North Carolina, Stati Uniti, 27157
- Wake Forest
-
-
Ohio
-
Cincinnati, Ohio, Stati Uniti, 45229
- Cincinnati Children's Hospital
-
-
Oregon
-
Portland, Oregon, Stati Uniti, 97239
- Oregon Health and Science University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19104
- Children's Hospital of Philadelphia
-
Pittsburgh, Pennsylvania, Stati Uniti, 15232
- University of Pittsburgh Medical Center
-
-
Rhode Island
-
Providence, Rhode Island, Stati Uniti, 02910
- Rhode Island Hospital
-
-
Texas
-
Dallas, Texas, Stati Uniti, 75235
- University of Texas Children's Medical Center
-
Dallas, Texas, Stati Uniti, 75235
- University of Texas Medical Center Clements
-
Houston, Texas, Stati Uniti, 77030
- Memorial Hermann Texas Medical Center
-
Houston, Texas, Stati Uniti, 77030
- Baylor Texas Children's
-
-
Wisconsin
-
Madison, Wisconsin, Stati Uniti, 53792
- University of Wisconsin- Madison
-
Milwaukee, Wisconsin, Stati Uniti, 53226
- Children's Hospital of Wisconsin
-
Milwaukee, Wisconsin, Stati Uniti, 53215
- Aurora St. Luke's Medical Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Viable neonates ≥ 3 kg at time of enrollment (as defined in Section 4.1) OR age greater than 28 days and less than 85 years of age at time of consent; AND
- Planned complex cardiac surgery with planned use of cardiopulmonary bypass, with an expectation of bleeding requiring platelet transfusion.
Exclusion Criteria:
- Expected order for washed or volume reduced platelets
- Patient with known anti-platelet antibodies
- Platelet transfusion refractoriness due to anti-HLA antibodies
- Known or suspected pregnancy
- Previously randomized in this study
- Conscious objection or unwillingness to receive blood products
- Known IgA deficiency
- Known congenital platelet disorder
- Known congenital bleeding disorder
- Planned post-operative extracorporeal membrane oxygenation (ECMO), ventricular assist device (VAD), and/or continuous renal replacement therapy (CRRT)/ hemodialysis
- Patients intended to receive whole blood either intra-operative or post-operative for bleeding
- Platelet transfusion (of any type) within 24 hours prior to the date of surgery
- Pre-operative thrombocytopenia, defined as platelet count <75x10(9)/L, based on the most recent labs completed within 72 hours prior to the date of surgery.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione sequenziale
- Mascheramento: Triplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Comparatore attivo: Room Temperature Platelets
Platelets stored at 20-24 degrees Celsius |
Platelets stored at 20-24 degrees Celsius |
|
Sperimentale: Cold Stored Platelets
Platelets stored at 1-6 degree Celsius |
Platelets stored at 1-6 degree Celsius |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Hemostatic Efficacy
Lasso di tempo: 24 hours after first study platelet transfusion
|
Assessed by a bleeding score, a modified Peri-Operative bleeding score: the score ranges from 1-5. A lower score signifies a better outcome. |
24 hours after first study platelet transfusion
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Chest Tube Output Through 24 Hours
Lasso di tempo: 24 hours from first study platelet transfusion or ICU admit (determined from which occurs last)
|
Chest tube output will be assessed by volume |
24 hours from first study platelet transfusion or ICU admit (determined from which occurs last)
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Blood Product Administration
Lasso di tempo: 24 and 72 hours from start time of first study platelet transfusion
|
The quantity of RBCs, Plasma, Platelets, Cryoprecipitate, and Whole blood |
24 and 72 hours from start time of first study platelet transfusion
|
|
Transfusion Associated Adverse Events
Lasso di tempo: within 7 days of first study platelet transfusion
|
As per CDC guidelines for transfusion associated adverse events |
within 7 days of first study platelet transfusion
|
|
Arterial Thrombotic Event
Lasso di tempo: within 7 days of first study platelet transfusion
|
Stroke, MI, aortic thromboic even |
within 7 days of first study platelet transfusion
|
|
Venous Thrombotic Event
Lasso di tempo: within 7 days of first study platelet transfusion
|
Deep vein thrombosis or pulmonary embolism confirmed by ultrasound, venography, perfusion scan, spiral CT, MRI, or pulmonary angiogram |
within 7 days of first study platelet transfusion
|
|
All Cause Mortality
Lasso di tempo: up to 28 days
|
Death for any reason |
up to 28 days
|
|
Total Dose of Individual Hemostatic Adjuncts (Units/kg)
Lasso di tempo: 24 and 72 hours from start time of first study platelet transfusion
|
Antifibrinolytic and coagulation factor concentrates |
24 and 72 hours from start time of first study platelet transfusion
|
|
Total Dose of Individual Hemostatic Adjuncts (mcg/kg)
Lasso di tempo: 24 and 72 hours from start time of first study platelet transfusion
|
Antifibrinolytic and coagulation factor concentrates |
24 and 72 hours from start time of first study platelet transfusion
|
|
Total Dose of Individual Hemostatic Adjuncts (mg/kg)
Lasso di tempo: 24 and 72 hours from start time of first study platelet transfusion
|
Antifibrinolytic and coagulation factor concentrates |
24 and 72 hours from start time of first study platelet transfusion
|
|
Total Dose of Individual Hemostatic Adjuncts (Grams/kg)
Lasso di tempo: 24 and 72 hours from start time of first study platelet transfusion
|
Antifibrinolytic and coagulation factor concentrates Epsilon-amino-caproic acid |
24 and 72 hours from start time of first study platelet transfusion
|
|
Mechanical Ventilation
Lasso di tempo: up to 28 days after first study platelet transfusion
|
Number of participants with need for mechanical ventilation |
up to 28 days after first study platelet transfusion
|
|
Length of Stay
Lasso di tempo: up to 28 days
|
ICU and hospital length of stay |
up to 28 days
|
|
Relative Change in Hemostatic Parameters at 6 and 24 Hours - Hemoglobin
Lasso di tempo: 6 and 24 hours after first study platelet transfusion
|
Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement) |
6 and 24 hours after first study platelet transfusion
|
|
Relative Change in Hemostatic Parameters at 6 and 24 Hours - Hematocrit
Lasso di tempo: 6 and 24 hours after first study platelet transfusion
|
Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement). |
6 and 24 hours after first study platelet transfusion
|
|
Relative Change in Hemostatic Parameters at 6 and 24 Hours- Platelet Count
Lasso di tempo: 6 and 24 hours after first study platelet transfusion
|
Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement) |
6 and 24 hours after first study platelet transfusion
|
|
Relative Change in Hemostatic Parameters at 6 and 24 Hours- INR
Lasso di tempo: 6 and 24 hours after first study platelet transfusion
|
Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement) |
6 and 24 hours after first study platelet transfusion
|
|
Relative Change in Hemostatic Parameters at 6 and 24 Hours- PTT
Lasso di tempo: 6 and 24 hours after first study platelet transfusion
|
Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement) |
6 and 24 hours after first study platelet transfusion
|
|
Relative Change in Hemostatic Parameters at 6 and 24 Hours- Fibrinogen
Lasso di tempo: 6 and 24 hours after first study platelet transfusion
|
Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement) |
6 and 24 hours after first study platelet transfusion
|
|
Unplanned Sternal Closure Delay
Lasso di tempo: prior to ICU admission
|
Sternum left open after cardiac surgery |
prior to ICU admission
|
|
Re-exploration for Bleeding
Lasso di tempo: 24 hours first study platelet transfusion
|
Return to OR after ICU admission |
24 hours first study platelet transfusion
|
|
Unplanned Extracorporeal Support Post Operatively
Lasso di tempo: within 48 hours of first study platelet transfusion
|
Unplanned placement on ECMO post operatively within 48 hours of 1st transfusion |
within 48 hours of first study platelet transfusion
|
|
Morbidities After ICU Admission
Lasso di tempo: within 7 days of first study platelet transfusion
|
Acute respiratory distress syndrome, need for and duration of renal support, renal failure, septic shock |
within 7 days of first study platelet transfusion
|
|
Measures of End Organ Injury- BUN and Creatinine
Lasso di tempo: within 48 hours of first study platelet transfusion worst value
|
If BUN, creatinine are collected clinically.- worst value |
within 48 hours of first study platelet transfusion worst value
|
|
Measures of End Organ Injury- Lactate
Lasso di tempo: within 48 hours of first study platelet transfusion worst value
|
If lactate was collected clinically. Worst value |
within 48 hours of first study platelet transfusion worst value
|
|
Measures of End Organ Injury- Troponin
Lasso di tempo: within 48 hours of first study platelet transfusion.
|
If lactate was collected clinically. Worst value |
within 48 hours of first study platelet transfusion.
|
|
Measures of End Organ Injury- ALT and AST
Lasso di tempo: within 48 hours of first study platelet transfusion.
|
If lactate was collected clinically. Worst value |
within 48 hours of first study platelet transfusion.
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Direttore dello studio: Philip C Spinella, MD, University of Pittsburgh
- Direttore dello studio: Marie E Steiner, MD, University of Minnesota
- Direttore dello studio: Nicole D Zantek, MD, University of Minnesota
Pubblicazioni e link utili
Pubblicazioni generali
- Krachey E, Viele K, Spinella PC, Steiner ME, Zantek ND, Lewis RJ. The design of an adaptive clinical trial to evaluate the efficacy of platelets stored at low temperature in surgical patients. J Trauma Acute Care Surg. 2018 Jun;84(6S Suppl 1):S41-S46. doi: 10.1097/TA.0000000000001876.
- Strandenes G, Sivertsen J, Bjerkvig CK, Fosse TK, Cap AP, Del Junco DJ, Kristoffersen EK, Haaverstad R, Kvalheim V, Braathen H, Lunde THF, Hervig T, Hufthammer KO, Spinella PC, Apelseth TO. A Pilot Trial of Platelets Stored Cold versus at Room Temperature for Complex Cardiothoracic Surgery. Anesthesiology. 2020 Dec 1;133(6):1173-1183. doi: 10.1097/ALN.0000000000003550.
- Zantek ND, Steiner ME, VanBuren JM, Lewis RJ, Berry NS, Viele K, Krachey E, Dean JM, Nelson S, Spinella PC. Design and logistical considerations for the randomized adaptive non-inferiority storage-duration-ranging CHIlled Platelet Study. Clin Trials. 2023 Feb;20(1):36-46. doi: 10.1177/17407745221126423. Epub 2022 Dec 21.
- Spinella PC, Zantek ND, VanBuren JM, Nicolson SC, Khanna AK, Klompas AM, Boisen ML, Williams TM, Monteleone M, Bashir DA, Pavey W, Smith BB, Ahmed MI, Niebler RA, Jeng E, Flynn BC, Joshi RV, Preuss JF, Goswami D, Yamada C, Lewis C, Cohn CS, Tint H, Kwak J, Sodha N, Simon ER, Van PY, Greilich PE, Booth FVM, Carter CP, Keegan A, Cap AP, Matuk J, McGlothlin A, Berry NS, Lewis RJ, Steiner ME; CHIPS Investigator Group. Cold and Room-Temperature Platelets in Cardiac Surgery: The CHIPS Randomized Clinical Trial. JAMA. 2026 Aug 17. doi: 10.1001/jama.2026.13328. Online ahead of print.
- Lewis AR, Peffley N, Klompas AM, Ashrani AA. Role of individual factor X concentrate pharmacokinetic studies in perioperative management of AL amyloidosis-associated acquired factor X deficiency. Transfusion. 2023 Sep;63(9):1773-1777. doi: 10.1111/trf.17477. Epub 2023 Jul 10.
- Klompas AM, Stubbs J. Massive transfusion protocol: What's in a name? Transfusion. 2023 Apr;63(4):896-897. doi: 10.1111/trf.17297. No abstract available.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- CHIPS
- W81XWH2090021 (Altro numero di sovvenzione/finanziamento: DoD)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .